

# Emerging Issues in the Art and Science of Pain and Symptom Management

## *FACULTY DISCLOSURE*

It is the policy of Beth Israel Medical Center and St. Luke's and Roosevelt Hospitals that faculty and providers disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). Beth Israel Medical Center and St. Luke's and Roosevelt Hospitals have policies in place to identify and resolve all conflicts of interest prior to this educational activity.

**Marilyn Bookbinder, RN, PhD** has received consulting fees from City of Hope and Ontario Case Care.

**Ricardo Cruciani, MD, PhD** has received fees from Merck and Pfizer, and has received a grant from OCB Pharma.

**Mitchell B. Max, MD** has received honorarium as a speaker for Merck.

**Richard Payne, MD** has served as a consultant for AstraZeneca, Elan, Ionix, Johnson & Johnson, Merck, Pfizer, Janssen, Purdue Pharma, Rinat, TheraQuest, Endo, Xanodyne, TransOral, Applied Clinical Intelligence, and PhRMA; has served on the speaker's bureau for King Pharmaceuticals; and is a major stock shareholder with Rinat, Xanodyne, and Prism Pharmaceuticals.

**Russell K. Portenoy, MD** is a consultant for Abbott, Adolar, Alpharma, Anesiva, Inc., Archimedes Pharma Ltd., Ascent Biomedical Ventures, Aveva Drug Delivery, Baxter Healthcare Corporation, Bayer, BioDelivery Sciences, International, Inc., Biometrix, Biovail, Cara Therapeutics, Cephalon, CombinatoRx, Inc., Cytogel, Endo Pharmaceuticals, Fralex, Genentech, Glaxo SmithKline, Globomax, GPC Biotech, Insys Therapeutics, Janssen Ortho-McNeil Pharmaceutical, Johnson & Johnson, King Pharmaceuticals, Ligand Pharmaceuticals, Merck, Nektar Therapeutics, Neuromed, Novartis, Paineceptor, PainReform, Pfizer, Pharms, PPD, Sarentis, Shire Pharmaceuticals, United Biosource Corp., Valeant Pharmaceuticals North America, Xenome Ltd., Xenon Pharmaceuticals, and Wyeth; and has received research grants (to the Department of Pain Medicine and Palliative Care) from Alpharma, Archimedes Pharma Ltd., BioDelivery Sciences International, Inc., Cephalon, CIMA Labs, Inc., Endo Pharmaceuticals, Glaxo SmithKline, GW Pharmaceuticals, Ligand Pharmaceuticals, Organon, Pfizer, Progenics, and ZARS, Inc.

**Edwin A. Salsitz, MD, FASM** has received honoraria as a speaker for Pfizer and for Reckitt-Benckiser.

The following have reported that they do not have any financial relationships to disclose:

### **FACULTY**

Terry Altilio, LCSW, ACSW  
Nessa Coyle, NP, PhD, FAAN  
Kathleen M. Foley, MD  
Myra Glajchen, DSW  
Subhash Jain, MD  
Pauline Lesage, MD, LLM  
Gavril W. Pasternak, MD, PhD  
Robert Sheu, MD

### **ORGANIZING COMMITTEE**

Marilyn Herleth, Winifred Schein